Closing on Nov. 17: Investor Calendar + Company Spotlight

INVESTOR NETWORK is the go-to, one-stop site for shareholders, clients and prospective investors

Imprimis Pharmaceuticals, Inc.

Imprimis Pharmaceuticals, Inc.

Sector: Pharmaceutical Preparations Region: CA, United States

: | Nasdaq: IMMY

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to producing and dispensing high quality innovative compounded medications in all 50 states. The company’s unique business model increases patient access and affordability to many critical medicines. Headquartered in San Diego, California, Imprimis owns and operates three production and dispensing facilities located in California, New Jersey and Pennsylvania. For more information about Imprimis, please visit the corporate website at

Investor Calendar

Nov 13, 2018 4:30 pm | 2018 Third Quarter Earnings

Aug 6, 2018 4:30 pm | Q2 Earnings Call

May 15, 2018 4:30 pm | Q1 Earnings Call

Mar 8, 2018 4:30 pm | Q4 Earnings Call

Latest Media

Warning! Third-party cookies must be enabled to view SlideShare presentations. ×

Having trouble?

Dropless cataract surgery with Dr. Tyson Schwiesow on the Fox 11 Living with Amy show.

Imprimis Pharmaceuticals, Inc. video

Dropless cataract surgery with Dr. Tyson Schwiesow on the Fox 11 Living with Amy show.

Imprimis Pharmaceuticals, Inc. video

Big Pharma Prioritises Profits Over Patients | Mark Baum | Oxford Union

Imprimis Pharmaceuticals, Inc. video

Company offers $1 alternative to Pharma Bro’s drug

Imprimis Pharmaceuticals, Inc. video

New Cataract Surgery Option

Imprimis Pharmaceuticals, Inc. video

Rising Cost of Drugs


Mark L. Baum, Chief Executive Officer, Member, Board of Directors
Mr. Baum is a founder, member of the board of directors and Chief Executive Officer of the company. In 2011, Mr. Baum led the restructuring and reorganization of Imprimis and since that time the company has raised over $60 million to build and support the growth of the company. Mr. Baum was appointed as a director of the company in December 2011, served as the Chairman of the board of directors from December 2011 to April 2012, and was appointed as Chief Executive Officer in April 2012. Prior to Mr. Baum’s involvement with Imprimis, from 2001 to 2011, he was the founder and managing director of TBLF, LLC, a consulting firm and fund manager, where he managed a series of three funds and acted as a principal investor in financing publicly traded companies or bridge-to-public equity transactions. Before his fund management experience, Mr. Baum founded and served as the president of YesRx, and practiced as a U.S. securities lawyer focused on public company reporting requirements and finance-related matters. Mr. Baum serves on the board of directors for Ideal Power, Inc., where he is also chairman of the audit committee. Mr. Baum is a senior advisor to Curology, Inc., a privately held venture capital backed dermatology focused business. Mr. Baum brings to the Imprimis Board years of public company executive experience, including knowledge of securities laws, reporting requirements and public company finance-related issues. Mr. Baum is an active participant in the national drug pricing and accessibility discussion, contributing through interviews for television, radio and print and advocating for policy changes to help ease the burden to patients and payors resulting from current drug pricing policies.
Andrew R. Boll, Vice-President, Accounting & Public Reporting
Mr. Boll has been the Chief Financial Officer of Imprimis Pharmaceuticals since February 2015. Mr. Boll oversees our accounting and financial reporting, investor relations, human resources and other operational departments. From February 2012 to January 2015, he was our Vice-President of Accounting and Public Reporting and was a consultant to our Company from December 2011 up to his hire date. Mr. Boll has led the accounting and certain financial efforts related to the restructuring and reorganization of Imprimis, and has overseen our pharmacy acquisitions, and integration processes of those pharmacies. Before joining Imprimis, from 2007 to 2011, Mr. Boll worked for BCGU, LLC, a privately-held fund manager, and its related entities, that specialized in capital venture-type investment opportunities. While at BCGU, he provided CFO/Controller consulting services to public company clients, compiling numerous SEC financial reports, and participating in several public company restructurings, financings and private to public mergers. Mr. Boll previously held various accounting roles at Welsh Companies, LLC, a privately held commercial real estate company, its fund and its other subsidiaries (during 2004 to 2007). Mr. Boll is a CFA charterholder, Certified Management Accountant and earned his B.S. degree in Corporate and Public Finance. He is a member of the Institute of Management Accountants, the CFA Institute, and the CFA Society of San Diego.
John Saharek, Vice-President of Commercialization, Ophthalmology
Mr. Saharek is a senior healthcare industry executive with over 30 years of broad experience developing and commercializing pharmaceutical, biotech, surgical device and diagnostic product portfolios. His results-oriented record of achievement includes designing and executing strategic commercial plans, building strong sustainable brands, launching new products, leading high performing teams and delivering outstanding results for a variety of healthcare companies. Over the past 15 years he has been focused in the ophthalmology segment where he has established valuable relationships with key opinion leaders and industry contacts. Mr. Saharek has been our Chief Commercial Officer since February 2015. Prior to that he served as our Vice-President of Commercialization, Ophthalmology since November 2012. Before joining Imprimis, he served as Head of U.S. Marketing and Strategy for ThromboGenics Inc., developing the commercial strategy and building a team to launch a new biologic into the US market. Prior to that he was Vice President, Business Development at SurModics Inc., working with both large and small pharmaceutical companies on multi-platform drug delivery initiatives in the U.S. and internationally. Early on in his career he held positions of increasing responsibility in both marketing and sales at a number of companies, including his tenure with Bausch & Lomb. Mr. Saharek has a Master’s of Business Administration from the University of Hartford and a Bachelor’s degree from Central Connecticut State University.
Clayton D. Edwards, Chief Operating Officer
Mr. Edwards oversees the company’s operations, including pharmacy, production, dispensing, customer service, Information Technology and quality. He joined Imprimis in August 2016 and served as the Senior Vice President of Operations until his promotion to Chief Operating Officer in April 2017. Mr. Edwards is a healthcare executive with over 30 years experience developing and operationalizing complex healthcare products and services. Prior to joining Imprimis, he was the Senior Vice President of Home Delivery Pharmacy and Prior Authorization for OptumRx, a UnitedHealthcare company. He led an $18B P&L business segment, developing and improving Traditional and Specialty Pharmacy, Prior Authorization, financial infrastructure, enterprise-wide information technology and robotic systems, as well as overall productivity. At OptumRx, Mr. Edwards grew the mail order pharmacy business to over 32 million prescriptions annually with six-sigma dispensing accuracy, directing a global staff of over 5,500 employees in pharmacy operations, prior authorization and appeals. He also helped in the development of a compounding formulary and network strategy for member pharmacies. Earlier in his career, he held various executive level positions at Doctor Diabetic Pharmacy/Sanare, Liberty Medical and Medco Health Solutions. Mr. Edwards actively serves on the Albany College of Pharmacy & Health Sciences Dean’s Advisory Counsel, where he graduated with his Pharmacy degree. He also has a Master’s degree in Business Administration from St. Joseph’s University.
Eric Rice, Vice President, Client Relations
Mr. Rice has been the Vice President of Client Relations at Imprimis since July 2016 and is responsible for implementing new processes to improve efficiencies with the ultimate goal of building Imprimis’ customer service department into a center of excellence.
Mr. Rice brings over 20 years of experience managing customer contact centers of varying sizes. Mr. Rice previously served as Vice-President of Philidor Rx Services, where he was responsible for the oversight of its call center operations comprised of over 550 agents, 40 supervisors, a workforce management, and quality and mentor teams. In his two years in that role he oversaw department growth from 60 to 600+ professionals and built a center of excellence that supported 10X dispensing volume growth. Previously, he served as Director of Strategy and Operation for Comcast Business Class. Before joining Comcast, Rice received his start in contact centers during his 20-year career with Prudential. Across that span, he held a variety of call center related positions, culminating with oversight of 20 call center departments across multiple locations.
Pramod Sharma, Vice President, Quality
Mr. Sharma has been the Vice President of Quality since August 2016 and oversees the expansion of all Imprimis quality systems in line with the highest pharmaceutical and compounding industry standards. Mr. Sharma has more than 15 years of quality assurance and quality control leadership skills, as well as laboratory management experience. He oversees all Imprimis quality programs. Included in these responsibilities is continuing to expand all Imprimis quality systems in line with the highest pharmaceutical and compounding industry standards. Prior to joining Imprimis, Mr. Sharma was the Senior Director of Research and Development Quality at Alvogen where he oversaw the quality production of sterile and non-sterile injectable, oral, topical, transdermal, and transmucosal drugs. He also served as the Senior Director of Quality at Albany Molecular Research and spent 7 years holding various positions at Akorn Inc., including the Executive Director of Quality Compliance, where he ensured successful adherence to cGMP requirements in multiple facilites, contributed to several successful NDA, ANDA and ANADA FDA submissions and represented Akorn in many FDA inspections of aseptic production processes. Mr. Sharma received his Ph.D. in Microbiology from the University of Oklahoma and performed postdoctoral research at Stanford University and Brookhaven National Laboratory.
Sanjay Samudre, Director of Manufacturing
Mr. Samudre has been the Director of Manufacturing at Imprimis since May 2016 where he oversees supply chain and production while adding automation and scalability to many of the company’s core compounded formulations. He brings to the company more than two decades of pharmaceutical supply chain, production management and operations experience. Prior to joining Imprimis, Mr. Samudre was Director of Operations at Teligent Pharma (formerly IGI Labs) where he provided leadership in functional pharmaceutical areas including manufacturing, packaging, engineering, process improvements and supply chain. He previously served as Plant Manager of Mediatech Inc., a division of Corning Life Sciences and as Production Manager at Qualitest Pharmaceuticals Inc., a subsidiary of Endo Health Solutions. Mr. Samudre also worked for Ciba Vision, the eye care unit of Novartis AG, as Production Manager to oversee manufacturing, filling and packaging operations. He has also held various positions with leading pharmaceutical companies Patheon, Apotex and Johnson and Johnson across Canada and India. Mr. Samudre received a Degree in Pharmacy from the University of Pune India in 1994.

News & Analysis